Intermittent Letermovir Dosing in Cytomegalovirus High‐Risk Liver Transplant Recipients May Facilitate Development of Cell‐Mediated Immunity and Prevent Post‐Prophylaxis Infection
Transplant Infectious Disease · 2026-07 · 28 (4)
DOI: 10.1111/tid.70244 ↗Kurz gefasst
Leserbrief in der Zeitschrift Transplant Infectious Disease, online erschienen am 19.05.2026. Verfasst von Hanna L Kleiboeker und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, University of Wisconsin Hospital and Clinics, Madison, Wisconsin, USA. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Department of Pharmacy, University of Wisconsin Hospital and Clinics, Madison, Wisconsin, USA.
- Department of Medicine, University of Wisconsin-Madison School of Medicine and Public Health, University of Wisconsin Hospital and Clinics, Madison, Wisconsin, USA.
Zitieren
APA
Kleiboeker, H. L., Saddler, C. M., & Jorgenson, M. R. (2026). Intermittent Letermovir Dosing in Cytomegalovirus High‐Risk Liver Transplant Recipients May Facilitate Development of Cell‐Mediated Immunity and Prevent Post‐Prophylaxis Infection. Transplant Infectious Disease, 28(4). https://doi.org/10.1111/tid.70244
Vancouver
Kleiboeker HL, Saddler CM, Jorgenson MR. Intermittent Letermovir Dosing in Cytomegalovirus High‐Risk Liver Transplant Recipients May Facilitate Development of Cell‐Mediated Immunity and Prevent Post‐Prophylaxis Infection. Transplant Infectious Disease. 2026;28(4). doi:10.1111/tid.70244
BibTeX
@article{Kleiboeker2026,
author = {Kleiboeker, Hanna L and Saddler, Chris M and Jorgenson, Margaret R},
title = {Intermittent Letermovir Dosing in Cytomegalovirus High‐Risk Liver Transplant Recipients May Facilitate Development of Cell‐Mediated Immunity and Prevent Post‐Prophylaxis Infection},
journal = {Transplant Infectious Disease},
year = {2026},
volume = {28},
number = {4},
doi = {10.1111/tid.70244}
}
EUVIMED